Compelling evidence associates functional CD8+ tumor-infiltrating lymphocytes (TIL) with increased survival of cancer patients [1]. However, tumors evolve to suppress T cells; TIL typically have a hypofunctional phenotype incapable of tumor clearance [2]. Exhaustion and tolerance are states of CD8+ T cell hypofunction that have been associated with TIL [1]. Many immunotherapies seek to restore or maintain antitumor function of CD8+ T cells [1]. As the mechanisms that restrict TIL function are elucidated, defining overlapping and exclusive pathways that restrict T cell function may accelerate identification of novel therapeutic targets.
T cell exhaustion is generally defined by accumulation of inhibitory receptors and gradual loss of functional capacities in response to persistent antigen stimulation and chronic inflammation [3,4]. Although exhausted CD8+ T cells have been most heavily characterized during chronic viral infections [5], similar states of exhaustion in TIL have been repeatedly documented in both murine and human tumors through phenotypic and functional characterization [3,4]. T cell tolerance controls inappropriate responses to self-antigens [3]. Many tumor-associated antigens recognized by CD8+ T cells are aberrantly expressed self-antigens [1,4]. Upon T cell receptor (TCR) stimulation, T cells lacking co-stimulation may undergo deletion or follow a transcriptional program toward a hypofunctional state of self-tolerance [3,6]. Self-tolerance characterization also includes loss of functional capacities and increased inhibitory receptor expression in some studies [1,6].
A pivotal genome-wide mRNA expression profile by Baitsch et al. of tumor-specific CD8+ T cells isolated from lymph node metastases (TILN) of vaccinated melanoma patients [4] showed that a gene set corresponding to exhausted CD8+ T cells [5] was enriched in TILN compared to functional counterparts [Gene set enrichment analysis (GSEA) [7,8]] (Figure 1). These results are not surprising because chronic inflammation and TCR stimulation are driving forces of TIL hypofunction during tumor growth [1]. Their supporting data showed TILN hypofunction and inhibitory receptor expression [4]. TILN were also compared to choice genes associated with deletional tolerance [9], but a genome-wide mRNA expression profile of self-tolerant CD8+ T cells was not yet available for systematic comparisons. Baitsch et al. therefore, concluded that exhaustion likely contributes to TILN hypofunction, but does not exclude the involvement of other transcriptional programs, such as self-tolerance [4]. Nevertheless, it has since become common for current literature to define hypofunctional TIL that express inhibitory receptors as “exhausted” [10,11].
Since a genome-wide mRNA expression profile of self-tolerant CD8+ T cells was recently made available by Schietinger et al. [6], we simultaneously analyzed TILN [4] for enrichment of genes associated with exhaustion [5] and self-tolerance [6] (Figure 2). We obtained statistics that adjust significance estimates for multiple hypothesis testing [7,8] (both self-tolerance and exhaustion FDR-corrected p-values <0.001). To our knowledge, these data are novel in that tumor-specific CD8+ T cells have not previously been systematically compared to self-tolerant CD8+ T cells. In light of the self-tolerant GSEA, the molecular and functional characterization by Baitsch et al. supports the conclusion that TILN [4] are exhausted and self-tolerant.
Because exhausted and self-tolerant CD8+ T cells share decreased functional capacity to proliferate in response to cognate antigen, it is of note that Schietinger et al. found the tolerance gene set to be associated with control of cell cycle (Figure 2B) [3]. Genes associated with cell cycle were also enriched among TILN and virally exhausted T cells when compared to their functional counterparts [4,5]. Enrichment of both gene sets in TILN further blurs the line between these states of hypofunctional CD8+ T cells. As T cell hypofunction varies by patient, malignancy, and over time, exhaustion and self-tolerance are not yet distinguishable by specific biomarkers [3]. These data show that unique non-overlapping gene expression defines TILN as heterogeneously exhausted and self-tolerant or as a distinct T cell program that partially overlaps with these T cell subsets (Table 1).
Table 1.
Exhaustion (78) | Self-tolerance (35) | Shared (4) | |||||||
---|---|---|---|---|---|---|---|---|---|
ACADM | CIT | HSPA8 | MDFIC | PLK4 | SH3BGRL | ADK | HIST1H2BN | RRM2 | CCNB1 |
ASCC1 | E2F8 | IDH2 | MKI67 | PON2 | SNRPB2 | ANLN | HIST1H3D | SGOL1 | LAG3 |
ATF1 | EIF2S1 | IFNG | NDFIP1 | PRKD2 | SS18 | AURKA | ITM2A | SNN | TNFRSF9 (4-1BB) |
CCL4 | ELL2 | IL6ST | NFIL3 | PTPN6 | SUPT4H1 | CD81 | KIF11 | SPAG5 | TOP2A |
CCND2 | ENG | IRF4 | NFKBIZ | RERE | TACC3 | CENPA | KIF2C | TCF19 | |
CCR5 | ENTPD1 | ISG20 | NR4A2 | RNF11 | TCF7 | CHAF1B | MARCKSL1 | TFRC | |
CCT8 | EVL | ITGA4 | NRP1 | RPA2 | TNFRSF1B | CHST3 | MCM2 | TPI1 | |
CD160 | FAM102A | ITGAE | NUCB1 | RSAD2 | TTC3 | FEN1 | MCM6 | XCL1 | |
CD244 | FAM134B | JAK3 | NXF1 | SDHA | UBR4 | H2AFX | PIF1 | ZRANB3 | |
CD7 | FOS | KLF10 | OSBPL11 | SELL | VAMP7 | HIST1H2BF | PKM2 | ||
CD9 | FYN | KPNB1 | PBX3 | SERPINB9 | WNK1 | HIST1H2BH | RAD54L | ||
CHEK1 | GZMK | LBR | PDK1 | SFMBT2 | ZFP36 | HIST1H2BJ | RCC1 | ||
CIRH1A | HMGCS1 | LCLAT1 | PELI1 | SGK1 | ZFP91 | HIST1H2BM | RRM1 |
Nevertheless, a shift in focus towards overlapping mechanisms that underlie exhaustion and self-tolerance may benefit those that seek to elicit a functional response by TIL [1]. For instance, inhibitory receptor LAG-3 and co-stimulatory receptor 4-1BB have been studied in the context of viral exhaustion, self-tolerance, and TIL hypofunction [5,12–15]. These GSEA data suggest that therapies against LAG-3 [16] and 4-1BB [14,15,17] may release tumor-specific CD8+ T cells from exhaustion and self-tolerance (Table 1).
Both viral-exhaustion and self-tolerance can be temporarily overridden to promote functional T cell responses [3]. Exhaustion occurs gradually upon chronic non-self TCR or immunostimulatory signals, whereas self-tolerance generally occurs quickly in response to initial TCR exposure to self-antigen when additional immunostimulatory signals are lacking [3]. Dissection of the overlapping and distinct gene expression between a tumor-specific CD8+ T cell program of hypofunction, exhaustion, and self-tolerance has widespread implications for development of cancer immunotherapies to mobilize TIL against both non-mutated self or mutated tumor antigens.
Acknowledgments
We thank Dr. Adam Burrack for providing editorial advice. KAW was supported by the National Institute of Health Grants 5T32AI007405 and 5R25GM083333, and a generous donation from Richard and Donna Hammel.
References
- 1.Waugh KA, Leach SM, Slansky JE. Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity. Vaccines (Basel) 2015;3:771–802. doi: 10.3390/vaccines3030771. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Baitsch L, Fuertes-Marraco SA, Legat A, Meyer C, Speiser DE. The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012;33:364–372. doi: 10.1016/j.it.2012.02.006. [DOI] [PubMed] [Google Scholar]
- 3.Schietinger A, Greenberg PD. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35:51–60. doi: 10.1016/j.it.2013.10.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Baitsch L, Baumgaertner P, Devêvre E, Raghav SK, Legat A, et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J Clin Invest. 2011;121:2350–2360. doi: 10.1172/JCI46102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27:670–684. doi: 10.1016/j.immuni.2007.09.006. [DOI] [PubMed] [Google Scholar]
- 6.Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science. 2012;335:723–727. doi: 10.1126/science.1214277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. Pgc-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34:267–273. doi: 10.1038/ng1180. [DOI] [PubMed] [Google Scholar]
- 9.Parish IA, Rao S, Smyth GK, Juelich T, Denyer GS, et al. The molecular signature of CD8+ T cells undergoing deletional tolerance. Blood. 2009;113:4575–4585. doi: 10.1182/blood-2008-10-185223. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Giordano M, Henin C, Maurizio J, Imbratta C, Bourdely P, et al. Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion. EMBO J. 2015;34:2042–2058. doi: 10.15252/embj.201490786. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265–276. doi: 10.1016/j.it.2015.02.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self-and tumor-tolerance systems. J Clin Invest. 2007;117:3383–3392. doi: 10.1172/JCI31184. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Snell LM, Lin GH, McPherson AJ, Moraes TJ, Watts TH. T-cell intrinsic effects of GITR and 4-1BB during viral infection and cancer immunotherapy. Immunol Rev. 2011;244:197–217. doi: 10.1111/j.1600-065X.2011.01063.x. [DOI] [PubMed] [Google Scholar]
- 14.Chester C, Ambulkar S, Kohrt HE. 4-1BB agonism: adding the accelerator to cancer immunotherapy. Cancer Immunol Immunother. 2016 doi: 10.1007/s00262-016-1829-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Chen S, Lee LF, Fisher TS, Jessen B, Elliott, et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol Res. 2015;3:149–160. doi: 10.1158/2326-6066.CIR-14-0118. [DOI] [PubMed] [Google Scholar]
- 16.Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917–927. doi: 10.1158/0008-5472.CAN-11-1620. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Berezhnoy A, Castro I, Levay A, Malek TR, Gilboa E. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest. 2014;124:188–197. doi: 10.1172/JCI69856. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. doi: 10.1038/nprot.2008.211. [DOI] [PubMed] [Google Scholar]
- 19.Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1–13. doi: 10.1093/nar/gkn923. [DOI] [PMC free article] [PubMed] [Google Scholar]